Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 5, 2010, Pages 1314-1322

  Roach III, MacK ^a   Bae, Kyounghwa ^b   Lawton, Colleen ^c   Donnelly, B J ^d   Grignon, David ^e   Hanks, Gerald E ^f   Porter, Arthur ^g   Lepor, Herbert ^h   Venketesan, Varagur ⁱ   Sandler, Howard ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e INDIANA UNIVERSITY   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j Cedars Sinai Hospital   (United States)

more..

Author keywords

Androgen deprivation therapy; Clinical trials; Prognostic factors; Prostate cancer; Radiation therapy; Serum testosterone

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CLINICAL TRIAL; PROGNOSTIC FACTORS; PROSTATE CANCERS; RADIATION THERAPY; SERUM TESTOSTERONE;

BODY FLUIDS; DISEASE CONTROL; DISEASES; EXPERIMENTS; PATHOLOGY; QUALITY ASSURANCE;

RADIOTHERAPY;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BASELINE SERUM TESTOSTERONE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; REFERENCE VALUES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 78549231887     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.09.073     Document Type: Article

References (37)

1. T. Imamoto, H. Suzuki, and S. Fukasawa Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy Eur Urol 47 2005 308 312
2. P. Iversen, F. Rasmussen, and I.J. Christensen Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma Scand J Urol Nephrol Suppl 157 1994 41 47
3. M. Ribeiro, P. Ruff, and G. Falkson Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer Am J Clin Oncol 20 1997 605 608
4. H.W. Daniell A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma Cancer 83 1998 1170 1173
5. S. Yamamoto, J. Yonese, and S. Kawakami Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy Eur Urol 52 2007 696 701
6. J.C. Massengill, L. Sun, and J.W. Moul Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy J Urol 169 2003 1670 1675
7. G. Schatzl, S. Madersbacher, and T. Thurridl High-grade prostate cancer is associated with low serum testosterone levels Prostate 47 2001 52 58
8. A.V. D'Amico, M.H. Chen, and S.B. Malkowicz Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less J Urol 167 2002 2025 2030 discussion 2030-2021
9. T.D. Denberg, R.C. Flanigan, and F.J. Kim Self-reported volume of radical prostatectomies among urologists in the USA BJU Int 99 2007 339 343
10. A.J. Armstrong, S. Halabi, and R. de Wit The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer Prostate Cancer Prostatic Dis 2008
11. A.V. D'Amico, A.A. Renshaw, and B. Loffredo Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy Cancer 110 2007 1723 1728
12. M. Roach 3rd Hormonal therapy and radiotherapy for localized prostate cancer: Who, where and how long? J Urol 170 2003 S35 S40 discussion S40-31
13. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
14. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
15. M. Roach, C. Marquez, and H. Yuo Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer Int J Radiat Oncol Biol Phys 28 1993 33 37
16. A.W. Partin, J. Yoo, and H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer J Urol 150 1993 10 14
17. C.T. Smith, P.R. Williamson, and A.G. Marson Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes Stat Med 24 2005 1307 1319
18. D. Collett Modelling survival data in medical research 1994 Chapman & Hall UK
19. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
20. Kaplan EL, Meier P. Non-parameteric estimation from incomplete observations. J Am Stat Assoc1958;53:457-481.
21. R. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
22. D.R. Cox Regression models and life tables J Royal Stat Soc 34 1972 187 202
23. J.G.R. Fine A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
24. C.T. Liverman, D.G. Blazer, Testosterone and aging: Clinical research directions 2004 National Academies Press Washington, DC
25. S. Bhasin, G.R. Cunningham, and F.J. Hayes Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline J Clin Endocrinol Metab 91 2006 1995 2010
26. J.P. Heaton Hormone treatments and preventive strategies in the aging male: Whom and when to treat? Rev Urol 5 Suppl 1 2003 S16 S21
27. M.M. Shores, A.M. Matsumoto, and K.L. Sloan Low serum testosterone and mortality in male veterans Arch Intern Med 166 2006 1660 1665
28. G.A. Laughlin, E. Barrett-Connor, and J. Bergstrom Low serum testosterone and mortality in older men J Clin Endocrinol Metab 93 2008 68 75
29. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 2005 1977 1984
30. R.M. Coward, J. Simhan, and C.C. Carson 3rd Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy BJU Int 103 2009 1179 1183
31. A. Morgentaler Testosterone therapy in men with prostate cancer: Scientific and ethical considerations J Urol 181 2009 972 979
32. M.F. Sarosdy Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy Cancer 109 2007 536 541
33. P.K. Agarwal, and M.G. Oefelein Testosterone replacement therapy after primary treatment for prostate cancer J Urol 173 2005 533 536
34. J.M. Kaufman, and R.J. Graydon Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men J Urol 172 2004 920 922
35. P.A. Kupelian, L. Potters, and D. Khuntia Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy >or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
36. A. Morales, A.M. Black, and L.E. Emerson Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: Preliminary observations BJU Int 103 2009 62 64
37. A.V. Taira, G.S. Merrick, and R.W. Galbreath Pretreatment serum testosterone and androgen deprivation: Effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy Int J Radiat Oncol Biol Phys 74 2009 1143 1149